ZUMA-25
Phase 2 Terminated
19 enrolled 28 charts
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Phase 2 Recruiting
496 enrolled
Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer
Phase 2 Completed
5 enrolled 10 charts
A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies
Phase 2 Completed
40 enrolled
Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Completed
140 enrolled
Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies
Phase 2 Completed
60 enrolled 10 charts
Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
94 enrolled 11 charts
Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Phase 2 Completed
77 enrolled 12 charts
Deferasirox for Treating Patients Who Have Undergone Allogeneic Stem Cell Transplant and Have Iron Overload
Phase 2 Terminated
1 enrolled 4 charts
Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation
Phase 2 Terminated
4 enrolled 4 charts
Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies
Phase 2 Completed
12 enrolled 11 charts
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma
Phase 2 Completed
63 enrolled 12 charts
Antithymocyte Globulin, Clofarabine, and Rituximab in Treating Patients After an Unsuccessful Stem Cell Transplant
Phase 2 Terminated
12 enrolled 12 charts
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
Phase 2 Terminated
200 enrolled 11 charts
Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant
Phase 2 Terminated
3 enrolled 10 charts
Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer
Phase 2 Completed
12 enrolled 10 charts
Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant
Phase 2 Completed
49 enrolled 4 charts
Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy
Phase 2 Completed
239 enrolled 23 charts
Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies
Phase 2 Withdrawn
Sunitinib in Treating Patients With Idiopathic Myelofibrosis
Phase 2 Terminated
14 enrolled 5 charts
Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment
Phase 2 Completed
70 enrolled
Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation
Phase 2 Unknown
80 enrolled
Biological Therapy Following Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Cancer
Phase 2 Completed
40 enrolled
Bone Marrow Transplantation in Treating Patients With Severe Aplastic Anemia or Rejection of Previous Bone Marrow Transplant
Phase 2 Terminated
Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant
Phase 2 Completed
171 enrolled
Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation
Phase 2 Completed
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis
Phase 2 Completed
37 enrolled
Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation
Phase 2 Completed
Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer
Phase 2 Completed
82 enrolled
Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer
Phase 2 Completed
Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant
Phase 2 Completed
53 enrolled
Immunotherapy in Treating Patients Who Are Undergoing Bone Marrow or Peripheral Stem Cell Transplantation
Phase 2 Completed
30 enrolled
Campath-1H + FK506 and Methylprednisolone for GVHD
Phase 2 Completed
34 enrolled
Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation
Phase 2 Completed
Bone Marrow Transplantation in Treating Patients With Hematologic Cancer
Phase 2 Completed